IONIS PHARMACEUTICALS INC business relationships

“Because we are leading the Phase 3 development program, we made an accounting policy election to recognize as non-customer revenue the cost-share funding from AstraZeneca, net of our share of AstraZeneca's development expenses, in the same period we incur the related development expenses.” SEC filing

“In 2023, we earned a $ 20 million license fee payment when we licensed rights to Latin America for WAINUA to AstraZeneca.” SEC filing

“There are numerous factors, most of which are not within our control, that could materially impact the amount and timing of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma.” SEC filing

“There are numerous factors, most of which are not within our control, that could materially impact the amount and timing of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma.” SEC filing

“...cant partner payments earned in the fourth quarter of 2024, including the $ 30 million milestone payment we earned from AstraZeneca when the MHRA approved WAINZUA for ATTRv-PN in the UK, $ 25 million payment we earned when AstraZeneca licensed a compound from us and $ 15 million milestone payment we...” SEC filing

“In 2023, we entered into a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with Lp(a)-driven CVD.” SEC filing

“Under our collaboration, AstraZeneca has licensed multiple medicines from us.” SEC filing

“Under these collaborations, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for certain neurological diseases and the option to license certain medicines resulting from these collaborations.” SEC filing

“In 2017, we initiated a collaboration with Novartis to develop and commercialize pelacarsen.” SEC filing

“Pursuant to our collaboration with Roche, Roche is responsible for any further drug supply for sefaxersen.” SEC filing

“Second Amended and Restated Strategic Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc. dated January 8, 2015 , filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and incorporated herein by reference.” SEC filing

“Amendment #5 to the Research, Development and License Agreement by and between the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated June 27, 2014 , filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30,...” SEC filing

“Therefore, we do not have any remaining performance obligations under our collaboration with GSK.” SEC filing

“through our distribution agreement with Swedish Orphan Biovitrum AB, or Sobi.” SEC filing

“In 2023, we entered into a royalty purchase agreement with Royalty Pharma in which Royalty Pharma receives 25 percent of our SPINRAZA royalty payments from 2023 through 2027, increasing to 45 percent of royalty payments in 2028, on up to $ 1.5 billion in annual SPINRAZA sales.” SEC filing

“In addition, we receive royalties from PTC Therapeutics International Limited, or PTC, for TEGSEDI and WAYLIVRA sales.” SEC filing

“In 2018, we entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries.” SEC filing

“Ionis Pharmaceuticals, Inc. In January 2015, we and Ionis Pharmaceuticals, Inc., or Ionis, entered into a second amended and restated strategic collaboration and license agreement, which we further amended in July 2015, or the 2015 Ionis agreement.” SEC filing

“Our revenue to date has been primarily generated from our current and former research collaborations with Bayer Consumer Care AG, or Bayer, Novartis Pharma AG, or Novartis, Ionis Pharmaceuticals, Inc., or Ionis, and Genentech Inc., or Genentech.” SEC filing

“License Agreement between Ionis Pharmaceuticals, Inc. and the Registrant dated as of October 26, 2018 (incorporated by reference to Exhibit 4.17 to the Registrant's Annual Report on Form 20-F for the fiscal year ended December 31, 2018 (File No. 001-36622) filed on March 28, 2019)” SEC filing

“Collaboration and License Agreement by and between the Registrant and Ionis Pharmaceuticals, Inc., dated November 10, 2022” SEC filing

“We are currently in Wave 1 of our collaboration with Ionis Pharmaceuticals, Inc. ("Ionis") focused on four disease targets in cardiometabolic indications.” SEC filing

“The other in-licensed patent family is owned by Ionis Pharmaceuticals, Inc., and is directed to compositions of matter of elsunersen.” SEC filing

“On September 11, 2019, the Company entered into both a Cooperation and License Agreement (the "License Agreement") with RogCon, Inc. ("RogCon"), and a Research, Collaboration, Option and License Agreement (the "Ionis Collaboration Agreement") with Ionis Pharmaceuticals, Inc. ("Ionis").” SEC filing

“| | | pursuant to our Collaboration and License Agreement with a subsidiary of Ionis Pharmaceuticals, Inc., or Ionis.” SEC filing